Pharmacokinetic Properties of the Novel Synthetic Cannabinoid 5F-APINAC and Its Influence on Metabolites Associated with Neurotransmission in Rabbit Plasma

The strong psychoactive effects of synthetic cannabinoids raise the need for the deeper studying of their neurometabolic effects. The pharmacokinetic properties of 5F-APINAC and its influence on metabolomics profiles associated with neurotransmission were investigated in rabbit plasma. Twelve rabbits divided into three groups received 1-mL 5F-APINAC at 0.1, 1 and 2 mg/kg. The intervention groups were compared with the controls. Sampling was performed at nine time points (0–24 h). Ultra-high-performance liquid chromatography–tandem mass spectrometry was used. The pharmacokinetics were dose-dependent (higher curve at a higher dose) with a rapid biotransformation, followed by gradual elimination within 24 h. The tryptophan concentrations abruptly decreased (p < 0.05) in all tested groups, returning to the basal levels after 6 h. 5-hydroxylindole acetic acid increased (p < 0.05) in the controls, but this trend was absent in the treated groups. The aspartic acid concentrations were elevated (p < 0.001) in the treated groups. L-kynurenine was elevated (p < 0.01) in the intervention groups receiving 1 mg/kg to 2 mg/kg. Dose-dependent elevations (p < 0.01) were found for kynurenic acid, xanthurenic acid and quinolinic acid (p < 0.01), whereas the anthranilic acid trends were decreased (p < 0.01). The indole-3-propionic acid and indole-3-carboxaldehyde trends were elevated (p < 0.05), whereas the indole-3-lactic acid trajectories were decreased (p < 0.01) in the intervention groups. 5F-APINAC administration had a rapid biotransformation and gradual elimination. The metabolites related to the kynurenine and serotonergic system/serotonin pathways, aspartic acid innervation system and microbial tryptophan catabolism were altered.

[1]  Alex Brito,et al.  Short- and long-term exposures of the synthetic cannabinoid 5F-APINAC induce metabolomic alterations associated with neurotransmitter systems and embryotoxicity confirmed by teratogenicity in zebrafish. , 2021, Comparative biochemistry and physiology. Toxicology & pharmacology : CBP.

[2]  H. Teixeira,et al.  The synthetic cannabinoids phenomenon: from structure to toxicological properties. A review , 2020, Critical reviews in toxicology.

[3]  Caroline Zangani,et al.  The e-Psychonauts’ ‘Spiced’ World; Assessment of the Synthetic 
Cannabinoids’ Information Available Online , 2020, Current neuropharmacology.

[4]  Jin-zhong Xiao,et al.  Potential Effects of Indole-3-Lactic Acid, a Metabolite of Human Bifidobacteria, on NGF-Induced Neurite Outgrowth in PC12 Cells , 2020, Microorganisms.

[5]  Alex Brito,et al.  In vivo and in vitro metabolism of the novel synthetic cannabinoid 5F-APINAC , 2019, Forensic Toxicology.

[6]  J. Horáček,et al.  Monitoring of kynurenine pathway metabolites, neurotransmitters and their metabolites in blood plasma and brain tissue of individuals with latent toxoplasmosis , 2019, Journal of pharmaceutical and biomedical analysis.

[7]  Stephen Gabrielson,et al.  Review of the many faces of synthetic cannabinoid toxicities , 2019, The mental health clinician.

[8]  Xiaoli Zhang,et al.  From inflammatory reactions to neurotransmitter changes: Implications for understanding the neurobehavioral changes in mice chronically infected with Toxoplasma gondii , 2019, Behavioural Brain Research.

[9]  Abeline R. Watkins.  Cannabinoid interactions with ion channels and receptors , 2019, Channels.

[10]  Harry Sokol,et al.  Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease. , 2018, Cell host & microbe.

[11]  C. Ríos,et al.  Relevance of Alternative Routes of Kynurenic Acid Production in the Brain , 2018, Oxidative medicine and cellular longevity.

[12]  G. Wegener,et al.  Drugs with antidepressant properties affect tryptophan metabolites differently in rodent models with depression‐like behavior , 2017, Journal of neurochemistry.

[13]  N. Moskaleva,et al.  HPLC–MS/MS method for the simultaneous quantification of desmethylmebeverine acid, mebeverine acid and mebeverine alcohol in human plasma along with its application to a pharmacokinetics study , 2017, Journal of pharmaceutical and biomedical analysis.

[14]  F. Tagliaro,et al.  In vivo metabolism of the new synthetic cannabinoid APINAC in rats by GC–MS and LC–QTOF-MS , 2017, Forensic Toxicology.

[15]  Gilles J. Guillemin,et al.  Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases , 2017, Neuropharmacology.

[16]  D. Shang,et al.  A Simple HPLC-MS/MS Method for Determination of Tryptophan, Kynurenine and Kynurenic Acid in Human Serum and its Potential for Monitoring Antidepressant Therapy. , 2017, Journal of analytical toxicology.

[17]  H. Gréen,et al.  Identification of AB-FUBINACA metabolites in authentic urine samples suitable as urinary markers of drug intake using liquid chromatography quadrupole tandem time of flight mass spectrometry. , 2016, Drug testing and analysis.

[18]  M. Huestis,et al.  Metabolic profiling of new synthetic cannabinoids AMB and 5F-AMB by human hepatocyte and liver microsome incubations and high-resolution mass spectrometry. , 2016, Rapid communications in mass spectrometry : RCM.

[19]  H. Rasmussen,et al.  Synthetic cannabimimetic agents metabolized by carboxylesterases. , 2015, Drug testing and analysis.

[20]  B. Brew,et al.  Quinolinic acid toxicity on oligodendroglial cells: relevance for multiple sclerosis and therapeutic strategies , 2014, Journal of Neuroinflammation.

[21]  B. Brew,et al.  Characterization of the kynurenine pathway in NSC‐34 cell line: implications for amyotrophic lateral sclerosis , 2011, Journal of neurochemistry.

[22]  D. Fuchs,et al.  The Potential Role of Cannabinoids in Modulating Serotonergic Signaling by Their Influence on Tryptophan Metabolism , 2010, Pharmaceuticals.

[23]  T. M. Souza,et al.  Acute intrastriatal administration of quinolinic acid provokes hyperphosphorylation of cytoskeletal intermediate filament proteins in astrocytes and neurons of rats , 2010, Experimental Neurology.

[24]  D. Fuchs,et al.  Δ9-Tetrahydrocannabinol and cannabidiol modulate mitogen-induced tryptophan degradation and neopterin formation in peripheral blood mononuclear cells in vitro , 2009, Journal of Neuroimmunology.

[25]  G. Rodchenkov,et al.  Possible Indirect Detection of rHuEPO Administration in Human Urine by High-Performance Liquid Chromatography Tandem Mass Spectrometry , 2008, European journal of mass spectrometry.

[26]  F. Muller,et al.  Denervation-induced skeletal muscle atrophy is associated with increased mitochondrial ROS production. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.

[27]  B. Szabo,et al.  Effects of cannabinoids on neurotransmission. , 2005, Handbook of experimental pharmacology.

[28]  A. Schousboe,et al.  Characterization of L-glutamate uptake into and release from astrocytes and neurons cultured from different brain regions , 2004, Experimental Brain Research.

[29]  L. Herbette,et al.  Alpha-bungarotoxin binding to acetylcholine receptor membranes studied by low angle X-ray diffraction. , 2003, Biophysical journal.

[30]  R. Reiter,et al.  Indole‐3‐propionic acid, a melatonin‐related molecule, protects hepatic microsomal membranes from iron‐induced oxidative damage: Relevance to cancer reduction , 2001, Journal of cellular biochemistry.

[31]  R. Schwarcz,et al.  The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[32]  T. Stone.  Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. , 2000, Trends in pharmacological sciences.

[33]  B. Poeggeler,et al.  Potent Neuroprotective Properties against the Alzheimer β-Amyloid by an Endogenous Melatonin-related Indole Structure, Indole-3-propionic Acid* , 1999, The Journal of Biological Chemistry.

[34]  F. Moroni,et al.  Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. , 1999, European journal of pharmacology.

[35]  M. Sawada,et al.  Tryptophan and its metabolite, kynurenine, stimulate expression of nerve growth factor in cultured mouse astroglial cells , 1998, Neuroscience Letters.

[36]  B. Brew,et al.  Chronic exposure of human neurons to quinolinic acid results in neuronal changes consistent with AIDS dementia complex , 1998, AIDS.

[37]  R. Stocker,et al.  Dramatic changes in oxidative tryptophan metabolism along the kynurenine pathway in experimental cerebral and noncerebral malaria. , 1998, The American journal of pathology.

[38]  R. Masters,et al.  The neurotransmitter revolution : serotonin, social behavior, and the law , 1994 .

[39]  R. Schwarcz,et al.  Blood–Brain Barrier Transport of Kynurenines: Implications for Brain Synthesis and Metabolism , 1991, Journal of neurochemistry.

[40]  R. Schwarcz,et al.  High-affinity uptake of L-kynurenine by a Na+-independent transporter of neutral amino acids in astrocytes , 1989, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[41]  T. Stone,et al.  Quinolinic acid effects on amino acid release from the rat cerebral cortex in vitro and in vivo , 1988, British journal of pharmacology.

[42]  G. Hanson,et al.  Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat , 1987, Neuropharmacology.

[43]  T. Stone,et al.  Quinolinic acid and other kynurenines in the central nervous system , 1985, Neuroscience.

[44]  R. Schwarcz,et al.  II: Excitotoxic models for neurodegenerative disorders , 1984 .

[45]  R. Schwarcz,et al.  Excitotoxic models for neurodegenerative disorders. , 1984, Life sciences.

[46]  T. Stone,et al.  Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. , 1981, European journal of pharmacology.